Observational Study for Multifocal Motor Neuropathy

(iMMersioN Trial)

Not currently recruiting at 134 trial locations

Overseen By Sabine s Coppieters, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: argenx

Disqualifiers: Other medical conditions, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to learn more about how individuals with Multifocal Motor Neuropathy (MMN), a nerve disorder that weakens muscles, manage their condition over time. Researchers will track participants' health and quality of life by observing regular doctor visits and gathering additional data. The trial does not test new treatments; instead, it focuses on understanding the condition better. Those diagnosed with MMN by a specialist might be suitable candidates for this study. As an unphased study, this trial offers a unique opportunity to contribute to a deeper understanding of MMN, potentially improving future care and management strategies.

Why are researchers excited about this trial?

Researchers are excited about this trial because it offers the opportunity to gather comprehensive, long-term data on adults with multifocal motor neuropathy (MMN). Unlike existing treatments, such as intravenous immunoglobulin (IVIG), which primarily manage symptoms, this study focuses on understanding disease progression over time. By tracking patients longitudinally, researchers hope to unveil new insights that could lead to more effective and targeted therapies in the future. This approach could ultimately enhance patient care by providing a deeper understanding of how MMN develops and responds to treatment.

Are You a Good Fit for This Trial?

Inclusion Criteria

You are able to provide written permission and meet the study requirements.

You have been diagnosed with MMN by a certified neurologist or neuromuscular specialist.

You are of legal age to consent to clinical studies as dictated by the local laws when signing the Informed Consent Form.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline

Participants follow their regular visit schedule with their treating physician, with an optional second visit for biomarker data collection

1-2 weeks

1 visit (in-person), optional 1 visit (in-person)

Follow-up

Participants are monitored for clinical outcomes, quality of life, and health care resource utilization

Long-term

What Are the Treatments Tested in This Trial?

Who Is Running the Clinical Trial?

argenx

Lead Sponsor

Trials

76

Recruited

11,500+

Tim Van Hauwermeiren

argenx

Chief Executive Officer since 2008

B.Sc. and M.Sc. in Bioengineering from Ghent University, Executive MBA from The Vlerick School of Management

Dr. Peter Ulrichts

argenx

Chief Medical Officer since 2023

MD from Maastricht University, PhD in Molecular Immunology from Maastricht University